Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak


News provided by

BioRadar UK Ltd.

21 Jun, 2011, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, June 21, 2011 /PRNewswire/ --

- Synthetic Replikins Therapeutics for E. Coli Now Available for Testing

Scientists Drs. Samuel and Elenore Bogoch of BioRadar UK Ltd. announced that retrospective studies indicate that an increase in Replikin Counts of the EHEC lethal strains of E. Coli preceded the current E. Coli outbreak. These EHEC strains of E. Coli have been studied in laboratories in Germany and elsewhere since 1995, and genome sequences are consequently available in the public databases.  Replikins are subsequences of the genome of an infectious agent that have been correlated with virulence across a range of diseases. Just as the H1N1 pandemic of 2009 was predicted in 2008 because of Replikin Count increases, E. Coli Replikin Counts (number of replikins per 100 amino acids) increased from 1.9 (+/- 1.2) in 2005, to 3.7 (+/- 2.9) in 2009 and to 14.2 in 2011. Twenty-nine individual Replikin sequences identified so far, conserved in the genomes of these hemorrhagic E. Coli strains, have been traced back from 2011: twenty-five of them to 1999, and four to 1995. To date, no other structures of infectious organisms have been described that correlate quantitatively and temporally with epidemic outbreaks, course, and lethality, and permit early or advance strain-specific warning of such outbreaks.

Replikins are genomic structures related to rapid replication, defined by Replikins Ltd. and BioRadar's proprietary and patented algorithm as peptides 7 to 50 amino acids long, containing two or more lysines, six to ten amino acids apart, at least one histidine, and a lysine concentration of 6% or more. As Replikins increase in number, they have been observed by linear and three-dimensional x-ray diffraction studies to expand and spread on the surface of the hemagglutinin gene of the influenza virus.

How reliable a signal is an increase in Replikin Count? To date, the Replikins science team has studied over 30,000 genomic sequences from a period of 94 years as published in PubMed. Statistically significant increases in Replikin Count (p<0.001) are consistently followed by or co-temporal with outbreaks. In a recent confirmation of reliability, the increases in Replikin Count were submitted for independent examination for the years 2002 to 2008, the years on which the 2008 prediction of the outbreak of the 2009 H1N1 pandemic had been based. The Replikin Count increases were found to be highly significant, namely, p values a) by t-test = 1/10 to the 130th power, b) by linear regression = 1/10 to the 24th power and 1/10 to the 29th power, c) by Spearman correlation < 2/10 to the 16th power, d) by Wilcoxon rank sum<1/10 to the 16th power, and e) by multiple regression adjusting for correlation between consecutive years = 2/10 to the 22nd power .

E. Coli now joins the group of pathogens in which outbreaks and/or increased lethality were found to be preceded by significant Replikin Count increases (p<0.001) in the pathogen one year or more in advance (Replikins Press <replikins.com>). These pathogenic outbreaks include influenza H5N1 (1997-2011), the influenza H1N1 pandemic (2002-2009), and its recurrence (2010), West Nile Virus outbreaks (2000-2008), Foot and Mouth Disease outbreaks (2009-2011), and the SARS outbreak (2002-2003). Rising E. Coli Replikin Counts also preceded rising mortality rates. This relationship has been found previously in malaria (Pl. Falciparum), in Taura Syndrome shrimp virus, where it predicted lethality, in H1N1 influenza, and in H5N1, where together with the increased lethality, the geographic localization was correctly predicted to be Indonesia (2006-2008).

The clinical significance of having a replikin count advanced warning is that such advanced warning will give health authorities more time to organize public health efforts and formulate vaccines even under old vaccine technology methods.  Replikins vaccine and therapeutic technology (consisting of solid phase synthesis in seven days) dramatically reduce the time and cost of production and accelerate distribution to a larger percent of the world's population as the solid phase synthesis vaccines do not require refrigeration.

Before the outbreak, in the case of the 2009 H1N1 pandemic, one year advance warning was provided by the Replikin technology. The TransFlu™ Replikins Vaccine was synthesized in 7 days and successfully tested in animals.*  After the H1N1 outbreak occurred in April 2009, the Replikins Count of the virus, was determined every few days 'real-time' in the 12,806 sequences published on PubMed throughout the course of the pandemic (2009-2010). There are two Replikin genes, one for infectivity and one for lethality.  The virus Replikin Count indicated that while infectivity would persist, lethality was rapidly declining. If this information had been more broadly utilized, much concern and cost could have been averted. If the rising Replikin Count of E. Coli in Germany had been observed two years ago, specific preventive and therapeutic countermeasures could have been implemented at that time. Even now, after the current E. Coli outbreak has begun, the projected course can be better defined with BioRadar genomic sequence analysis and Replikin countermeasures are available for testing.

For information regarding the BioRadar Global Surveillance System™ and on synthetic Replikins vaccines and therapeutics now available for testing, contact aborsanyi@replikins.com.

*Jackwood MW, et al. Efficacy of a Replikin peptide Vaccine Against Low Pathogenicity Avian Influenza H5 Virus. Avian Diseases 53(4): 613-617, 2009.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.